Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 30, 2015
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Feb. 16, 2016. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review fourth quarter and full year financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Feb. 16. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of ...
December 16, 2015
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a first quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share, an increase of 14.5% from the quarterly dividend rate paid in 2015. The dividend is to be paid on Tuesday, March 1, 2016, to holders of record on Thursday, Jan. 21, 2016. “Zoetis has continued to distinguish itself as a world leader in the growing animal health industry this year, based on our global scale, diverse portfolio and track record of innovation. We continue to invest in critical internal and external growth opportunities for Zoetis that create value, while returning excess capital to our shareholders,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “With the Board’s approval, I am pleased to announce we are increasing our dividend by 14.5% as we head into 2016 and continuing our commitment to effective and efficient use of our cash.” About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, ...
December 14, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. EST (9:30 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated ...
November 17, 2015
Gives Veterinarians New Choice to Treat Fleas, Ticks and Sarcoptic Mange in Dogs Aged Eight Weeks and Older Innovation from Zoetis Targets Growing Demand for Oral Flea and Tick Medication Zoetis Inc. today announced that the European Commission has granted marketing authorization for Simparica TM (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age. The approval follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in September 2015. “The approval of Simparica gives veterinarians a new oral choice in parasite control for dogs,” said Dr. Balázs Capári, veterinary specialist, small animal medicine, in Sümeg, Hungary, who participated in clinical trials of Simparica.1 “In my experience, Simparica has been shown to rapidly kill fleas and ticks with efficacy that persists for five weeks. Dog owners participating in the trials also reported that Simparica ...
November 10, 2015
Zoetis Inc . (NYSE:ZTS) today announced that it has completed the purchase of PHARMAQ , the global leader in vaccines and innovation for health products in aquaculture, for a price of $765 million on a debt-free basis, having fulfilled all closing requirements. Zoetis purchased PHARMAQ from a company owned by Permira IV, a fund managed by the global investment firm Permira, which has been the majority owner of the company since 2013. “We are very pleased to welcome the PHARMAQ team to Zoetis, and we look forward to the future success we can build together as a market leader in aquatic health,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “The PHARMAQ people, products and late-stage pipeline give Zoetis a strong platform for growth in the fastest growing animal health market.” Zoetis plans to run the PHARMAQ business largely as a stand-alone operation within the company to help maintain its focus on critical customer needs and R&D milestones that will assure continued success. ...
November 9, 2015
Zoetis Inc. (NYSE:ZTS) announced today that it has agreed to sell $1.25 billion of senior notes: $500,000,000 in aggregate principal amount of 3.450% senior notes due 2020 and $750,000,000 in aggregate principal amount of 4.500% senior notes due 2025, in an underwritten public offering. Zoetis intends to use the net proceeds to repay amounts drawn under its revolving credit facility, which were borrowed to fund the purchase price for the acquisition of PHARMAQ; to repay the principal when due of its 1.150% senior notes due 2016 in the aggregate principal amount of $400 million; and for general corporate purposes. The offering is expected to close on November 13, 2015, subject to customary closing conditions. Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Capital Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may ...
November 5, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the 27 th Annual Piper Jaffray Healthcare Conference on Tuesday, Dec. 1, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. They are scheduled to present at 9:30 a.m. EST. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests ...
November 3, 2015
Delivers 9% Operational Growth in Revenue and 31% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange Third Quarter 2015 Reported Revenue of $1.2 Billion Was Flat Compared to Third Quarter 2014 Third Quarter 2015 Reported Net Income of $189 Million, or $0.38 Per Diluted Share, Increased 14% and 15%, Respectively, Compared to Third Quarter 2014 Third Quarter 2015 Adjusted Net Income 1 of $252 Million, or Adjusted Diluted EPS 1 of $0.50, Increased 22% Compared to Third Quarter 2014 Updates Full Year 2015 Revenue Guidance to $4.700 - $4.750 Billion and Full Year 2015 Adjusted Diluted EPS 1 Guidance to $1.70 - $1.74 Updates Financial Outlook for Full Year 2016 and 2017 Zoetis Inc . (NYSE:ZTS) today reported its financial results for the third quarter of 2015, and updated its full year 2015 guidance, as well as its financial outlook for full year 2016 and 2017. The company reported revenue of $1.2 billion for the third quarter of 2015, which was flat compared to the third ...
November 2, 2015
Purchase price of $765 million Strengthens core livestock business with industry-leading vaccines and pharmaceuticals for farmed fish, the fastest growing segment of animal health industry Gains late-stage pipeline anticipated to bring several new products to market in the near term Affirms value creation strategy to deploy capital to strengthen the portfolio and support future growth Zoetis Inc . (NYSE:ZTS) today announced an agreement to purchase PHARMAQ , the global leader in vaccines and innovation for health products in aquaculture, for a price of $765 million on a debt-free basis. Acquiring PHARMAQ strengthens Zoetis’ core livestock business, giving the company a market-leading presence in the fastest growing segment of the animal health industry. Zoetis is purchasing PHARMAQ from a company owned by Permira IV, a fund managed by the global investment firm Permira, which has been the majority owner of the company since 2013. PHARMAQ is the market leader in sales of vaccines for ...
October 1, 2015
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share. The dividend is to be paid on Tuesday, Dec. 1, 2015, to holders of record on Thursday, Nov. 5, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com . DISCLOSURE NOTICES ...
September 30, 2015
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Nov. 3, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review third quarter 2015 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 3. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In ...
September 22, 2015
Zoetis recognized by Working Mother magazine for commitment to providing colleagues with opportunities for growth, advancement and work-life balance Senior Principal Scientist Raksha Tiwari named Zoetis Working Mother of the Year Zoetis Inc . (NYSE:ZTS) today announced that it has been named among the top ten on Working Mother magazine’s "100 Best Companies for Working Mothers" list for the second consecutive year. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as flexibility, advancement, paid family leave and childcare. “Zoetis is honored to once again be named one of Working Mother magazine’s top ten companies for working moms,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer at Zoetis. “Zoetis is committed to cultivating an environment where everyone can balance their work and life responsibilities. We are proud to be recognized for our leadership in ...
August 20, 2015
Investment enhances company’s capacity to produce high quality animal health products and reinforces commitment to the community Zoetis Inc. today marked the completion of a 19,000-square-foot, three-story expansion at its manufacturing facility in Lincoln, Neb., with a ribbon-cutting ceremony attended by Lincoln Mayor Chris Beutler. Through increased production at the facility, Zoetis is affirming its position as a global leader and world-class manufacturer of high-quality animal health products and an employer of choice in Lincoln. “Zoetis is excited to expand its footprint in Lincoln and provide veterinarians, livestock producers, pet owners and the animals in their care with a reliable, consistent supply of quality animal health products,” said Betty Mason, site leader in Lincoln. “The entire community can be proud of our expanded manufacturing operations, which enable us to produce 1,200 finished goods for more than 100 markets around the world.” The site is one of the largest ...
August 18, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the 2015 Morgan Stanley Global Healthcare Conference on Friday, Sept. 18, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. They are scheduled to present at 1:35 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the ...
August 5, 2015
Sydney, New South Wales, Australia - August 5, 2015 – Zoetis today announced that the Hendra virus vaccine,Equivac ® HeV, has received registration from the Australian Pesticides and Veterinary Medicines Authority (APVMA). “We at Zoetis are pleased that after nearly three years of positive uptake, Equivac® HeV vaccine has successfully been registered,” said Lance Williams, General Manager for Zoetis in Australia and New Zealand. “The APVMA undertakes one of the most detailed assessment processes in the world before approving registration of a product and Equivac HeV passed every assessment criteria for registration. Equivac HeV demonstrates Zoetis’ commitment to providing horse owners with quality animal health solutions they can count on.” Equivac HeV was first made available in November 2012, in response to the growing number of outbreaks and subsequent horse deaths in Queensland and New South Wales.  The full registration comes one week after reports of a second Hendra virus ...
August 4, 2015
Delivers 11% Operational Revenue Growth and 20% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange Records $263 Million in Charges Related to Comprehensive Operational Efficiency Initiative, Resulting in Net Loss of $37 Million, or Net Loss per Diluted Share of $0.07 Second Quarter 2015 Revenue of $1.2 Billion Increased 1% Second Quarter 2015 Adjusted Net Income 1 of $216 Million, or Adjusted Diluted EPS 1 of $0.43, Increased 14% and 13%, Respectively Updates Full Year 2015 Revenue Guidance to $4.700 - $4.775 Billion Updates Full Year 2015 Adjusted Diluted EPS 1 Guidance to $1.63 - $1.68 Zoetis Inc . (NYSE:ZTS) today reported its financial results for the second quarter of 2015 and updated its full year 2015 guidance. The company reported revenue of $1.2 billion for the second quarter of 2015, which increased 1% compared to the second quarter of 2014. Revenue reflected an operational2 increase of 11%, excluding the impact of foreign exchange. The net loss for the ...
August 3, 2015
First targeted antibody therapy approved for control of clinical signs of atopic dermatitis in dogs Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. It represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientific insights into the pathway of allergic skin conditions. “The introduction of Canine Atopic Dermatitis Immunotherapeutic* will provide veterinarians an innovative new option to address this very challenging skin condition,” said Thomas Lewis II, DVM, DACVD, who participated in clinical studies of this antibody therapy and is a veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz.** “By helping to relieve itching and the clinical signs associated ...
July 21, 2015
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a third quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share. The dividend is to be paid on Tuesday, Sept. 1, 2015, to holders of record on Thursday, Aug. 13, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com . DISCLOSURE NOTICES ...
June 30, 2015
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, Aug. 4, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review second quarter 2015 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Aug. 4, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a ...
June 2, 2015
Today the U.S. Food and Drug Administration published the finalized Veterinary Feed Directive (VFD). This regulation mandates the rules and responsibilities of licensed veterinarians in prescribing and administering medically important antibiotics in feed. We are reviewing the Veterinary Feed Directive in detail. We support the intent of the Veterinary Feed Directive (VFD) regulation to guide veterinarians and farmers as they manage the health and welfare of animals. We believe that veterinarians should be involved in decisions regarding antibiotic use in food animals for the health of the animal and for the safety of the food supply. Zoetis is committed to supporting our veterinary and livestock producer customers to make a successful transition to the new procedures outlined in the VFD. Zoetis continues to remove growth promotion uses of medically important antibiotics now that the VFD regulation is finalized. These updates to the VFD were made in conjunction with ...
May 21, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the William Blair 35 th Annual Growth Stock Conference on Wednesday, June 10, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:40 p.m. (EDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at ...
May 5, 2015
First Quarter 2015 Revenue of $1.1 Billion Was Flat Compared to First Quarter 2014; an Increase of 6% Excluding Foreign Exchange First Quarter 2015 Reported Net Income of $165 Million, or $0.33 per Diluted Share, Increased 6% First Quarter 2015 Adjusted Net Income 1 of $207 Million, or Adjusted Diluted EPS 1 of $0.41, Increased 8%; an Increase of 14% Excluding Foreign Exchange Announces Comprehensive Initiative to Simplify Operations, Improve Cost Structure, and Better Allocate Resources to Generate Cost Savings of Approximately $300 Million by 2017 Updates Full Year 2015 Revenue Guidance to $4.675 - $4.775 Billion and Reaffirms Full Year 2015 Adjusted Diluted EPS 1 Guidance of $1.61 - $1.68 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2015 and announced a comprehensive operational efficiency initiative to enhance its long-term competitive position and profitability. The company also updated its guidance for full year 2015 and provided ...
May 1, 2015
Speaking to shareholders at the Zoetis Inc . (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix highlighted the company’s 2014 performance and strategies for future growth as the global market leader in animal health. “In our second year as a public company, we generated strong profitable growth, built on the core strengths of our business model and continued to create value for our customers and shareholders,” said Alaix. “This year, we will continue to enhance and protect our competitive advantages, improve our working capital efficiency, achieve margin improvements and return excess capital to shareholders.” Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. Preliminary results of shareholder voting from the meeting are as follows: Sanjay Khosla, Dr. Willie M. Reed and William C. Steere, Jr. have been elected as directors for three-year terms. Shareholders voted to approve the ...
April 28, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the BMO Capital Markets 10 th Annual Farm to Market Conference on Thursday, May 21, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:00 p.m. (EDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees ...
April 14, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, in Las Vegas, Nev. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 6:00 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide ...
April 13, 2015
Zoetis Inc . (NYSE:ZTS) today announced that its Board of Directors has appointed Paul M. Bisaro, Executive Chairman of Actavis plc, to the company’s Board of Directors. Mr. Bisaro’s term will begin immediately following the company’s 2015 Annual Meeting of Shareholders, which is scheduled for May 1, 2015. With the addition of Mr. Bisaro, the Zoetis Board will expand to 11 directors, and he will serve on the Compensation Committee. “We are pleased to announce that Paul will join the Zoetis Board,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “He brings extensive business leadership and global healthcare experience to Zoetis, along with a deep understanding of the pharmaceutical industry. He will be a valuable addition to our board as we continue to grow our position as the world’s leading animal health company.” Mr. Bisaro has more than 20 years of experience in the healthcare industry. He is Executive Chairman of Actavis plc, a global pharmaceutical company focused on ...
March 31, 2015
Zoetis Inc . (NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, May 5, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review first quarter 2015 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on May 5, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range ...
March 19, 2015
LONDON, UK - March 19, 2015 - Leading animal health company Zoetis Inc. unveiled its Centre for Digital Innovation (CDI) at the House of Lords today. Opened in the heart of London’s Tech City, the new Centre will create sophisticated digital products that enable data-driven decision-making to enhance precision farming and improve animal wellbeing for livestock and pets. Hosted by Lord Trees, the event was introduced by Lord de Mauley and attended by industry representatives including the National Farmers Union and those with an interest in the success of UK farming, among them some of the large supermarket chains. The production of high-quality food for an expanding population in a world of finite resources has put precision farming firmly on the Centre’s agenda. The statistics are compelling: a global population increase of 30% between 1990 and 2010 2 has led to a greater demand for animal protein and need for productivity improvements; seven billion people worldwide consume protein ...
March 16, 2015
Experts in animal and human health called on the medical, veterinary, public health and related healthcare communities to collaborate more closely to prevent and combat diseases on two fronts: Infectious diseases that can be passed between animals and people, such as influenza, rabies, Ebola virus and West Nile virus Diseases that are common to animals and people, such as  arthritis, cancer, diabetes and allergies AMSTERDAM, THE NETHERLANDS - March 16, 2015 - A panel of experts in both human and animal healthcare called for greater collaboration in combating the increasing threat of animal-transmitted infectious diseases and to more effectively innovate under the umbrella of One Health to prevent and treat chronic diseases that are common to animals and people. This call to action came at a satellite symposium held today at the 3rd International One Health Congress in Amsterdam*. The event was sponsored by the animal health company Zoetis. People and Animals are More Closely Linked ...
March 2, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the Jefferies 2015 Animal Health Summit on Thursday, March 26, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. EDT. The presentation is not scheduled to be webcast. Investors and other interested parties will be able to access the presentation materials at http://investor.zoetis.com/events-presentations at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning ...
February 27, 2015
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share. The dividend is to be paid on Tuesday, June 2, 2015, to holders of record on Thursday, April 9, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com . DISCLOSURE NOTICES ...
February 18, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 12, in Miami, Fla. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:15 a.m. EST. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of ...
February 11, 2015
Fourth Quarter 2014 Revenue of $1.3 Billion Increased 5% Compared to Fourth Quarter 2013 Fourth Quarter 2014 Reported Net Income of $126 Million, or $0.25 per Diluted Share, Increased 20% and 19%, respectively Fourth Quarter 2014 Adjusted Net Income of $203 Million, or Adjusted Diluted EPS 1
of $0.40, Increased 13% and 11%, respectively Full Year 2014 Revenue of $4.8 Billion Increased 5%; Adjusted Net Income of $790 Million, or Adjusted Diluted EPS 1 of $1.57, Increased 11% Full Year 2015 Guidance Updated to Revenue of $4.8 - $4.9 Billion and Adjusted Diluted EPS 1 of $1.61 - $1.68 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2014 and updated its guidance for full year 2015. The company reported revenue of $1.3 billion for the fourth quarter of 2014, an increase of 5% from the fourth quarter of 2013; revenue reflected an operational2 increase of 9%, excluding the impact of foreign currency. Net income for the fourth quarter of ...
February 10, 2015
Zoetis Inc . (NYSE:ZTS) today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements. The purchase expands Zoetis’ companion animal product portfolio to bring veterinarians solutions for anesthesia and treating pain and serious illnesses such as diabetes. It also brings novel cancer and pain compounds to the Zoetis pipeline for further development. “We believe Zoetis’ scale, industry-leading field force, and global presence will rapidly expand the reach and penetration of these newly acquired, leading brands for the veterinary surgical suite,” said Zoetis Group President Kristin Peck, who oversees the company’s Strategy and Corporate Development organization. “The acquisition is a prime example of our value creation strategy to deploy capital to acquire products that enhance our portfolio and enable us to deliver more customized solutions to veterinarians.” In conjunction with ...
February 6, 2015
Zoetis Inc . (NYSE:ZTS) will participate in the Cowen and Company 35th Annual Health Care Conference on Wednesday, Mar. 4, in Boston, Mass. Kristin Peck, Executive Vice President and Group President, will represent the company and respond to questions from analysts. She is scheduled to present at 10:40 a.m. EST. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 ...
February 4, 2015
Zoetis Inc. (NYSE:ZTS), the world’s leading animal health company, today announced that its Board of Directors has appointed William F. Doyle, a Member of Pershing Square Capital Management’s Investment Team, to the company’s Board of Directors, effective February 3. With the addition of Mr. Doyle, the Zoetis Board will expand to 10 directors. Zoetis and Pershing Square reached an agreement providing for Mr. Doyle’s election as well as the election in the future of an additional independent director mutually acceptable to Zoetis and Pershing Square. “We welcome Bill to the Zoetis Board,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “He brings significant expertise and relevant industry and operational experience to Zoetis and I am confident he will provide valuable insight and perspectives as we continue to enhance our position as the world leader in animal health.” “As the industry leader in the animal health market, Zoetis is an exceptional company with a diverse product ...
January 13, 2015
Findings Published in Journal of Community and Supportive Oncology Are First to Show Improvement in Emotional Well-Being and Quality of Life Trial Conducted at Mount Sinai Beth Israel with Support from The Good Dog Foundation, Zoetis and Pfizer Foundation New York, NY – January 13, 2015 — Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients. The research was made available this week in the Journal of Community and Supportive Oncology . The study, conducted by researchers at Mount Sinai Beth Israel, found that patients receiving intensive multi-modal concomitant radiation therapy and chemotherapy for gastrointestinal, head or neck cancers experienced increases in emotional well-being and quality of life when they received visits from a certified therapy dog during the course of their treatment. Increases in emotional well-being were ...
January 12, 2015
NOTTINGHAM, UK - Jan. 12, 2015 -The University of Nottingham has secured funding from Biotechnology and Biological Sciences Research Council (BBSRC) to undertake a four-year project with Zoetis, the leading global animal health company, with the aim of improving feed efficiency in pig farming. This new project builds on an ongoing partnership between The University of Nottingham and Zoetis and will focus on studies to help maximize muscle growth and improve the health of pig herds on farms. Funding for the research initiative will be in excess of £800k, including the contribution from Zoetis. John Brameld, Associate Professor in Nutritional Biochemistry at The University of Nottingham and principal investigator, said: "We are very excited to be partnering with Zoetis on such a significant research project which could potentially help to benefit farmers across the globe." "Improving feed efficiency in farm animals such as pigs is becoming increasingly important in order to ensure their ...
January 7, 2015
Additional label claims help protect pigs from PRRS at every production stage FLORHAM PARK, N.J., Jan. 7, 2015 — Fostera® PRRS, from Zoetis, is now licensed for whole herd protection against both the respiratory and reproductive forms of disease caused by porcine reproductive and respiratory syndrome (PRRS) virus. The new reproductive claim, recently granted by the U.S. Department of Agriculture (USDA), allows for vaccination of sows and gilts prebreeding to help provide protection against the reproductive form of the disease. The new respiratory claim allows for vaccination of pigs 1 day of age or older against the respiratory form of the disease. With the new claims, Fostera PRRS is now the first and only PRRS modified-live virus (MLV) vaccine to be licensed for the vaccination of healthy, susceptible swine 1 day of age or older in PRRS virus-positive herds to: Aid in preventing reproductive disease with a duration of immunity of at least 19 weeks* Aid in preventing respiratory ...